Pars Planitis Market
Number of pages: 100 | Report Format: PDF | Published date: March 07, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 494 million |
|
Revenue Forecast in 2031 |
US$ 869 million |
|
CAGR |
6.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Therapy, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global pars planitis market was valued at US$ 494 million in 2022 and is expected to register a revenue CAGR of 6.5% to reach US$ 869 million by 2031.
Pars Planitis Market Fundamentals
Pars planitis is a chronic idiopathic intermediate uveitis primarily affecting children and adolescents. The most typical symptoms that appear are floaters and blurred vision. Snowballs, snowbanks, haze, and diffuse vitreous cells are common pars planitis observations. Nevertheless, pars planitis is often a benign type of uveitis; complications such as cataracts, cystoid macular edema, vitreous opacities, and optic disc edema can cause the condition to become potentially blinding. Floaters and blurred vision are the most prevalent symptoms at the time of appearance. In severe cases, macular edema or the accumulation of floaters in the vitreous can cause a substantial loss of vision. The illness may be asymptomatic and discovered by chance during a routine eye exam, particularly in young children. Infants may even exhibit strabismus as a result of complications that result in leukocoria or the development of amblyopia. Although pars planitis is typically a benign type of uveitis, there is a wide range in the clinical severity of the condition. The diagnosis of pars planitis is frequently delayed as the anterior section is frequently quiet, and the symptoms are mild, which causes complications and permanent vision loss in young children. The stepladder approach is the most popular technique for treating patients with pars planitis. But different practitioners follow different orders for the procedures. A four-step process was previously used. First, if periocular corticosteroid injections are deemed ineffective, they are followed by oral prednisone. The use of corticosteroids, which are still the basis of treatment, is the first move in current practice.
[576575]
Pars Planitis Market Dynamics
Since most cases of intermediate uveitis in children have no underlying disease, they are categorized as idiopathic intermediate uveitis or pars planitis. The incidence and prevalence of the illness exhibit significant variation according to the patients' geographic, genetic, and referral patterns. 1.4 to 2 cases per 100,000 people have been recorded as its annual incidence in studies carried out in France and the United States. According to various studies, pars planitis causes 5.7% to 26.7% of pediatric uveitis. The increase in pars planitis prevalence is a key factor responsible for the significant revenue growth of the global pars planitis market.
The rising cost of healthcare is a major factor affecting the market for pars planitis treatments. Important factors in an economy are healthcare expenditure and its effects on economic performance. Healthcare spending has grown, which has improved human capital productivity and contributed to economic growth. Therefore, the increasing healthcare expenditure contributes to the expansion of the pars planitis market.
The pars planitis market is also growing owing to the surging healthcare rate. Furthermore, growing government funding, increasing awareness and raising efforts by both public and private organizations, and advancements in medical technology are expected to drive the pars planitis treatment market revenue growth. The market for treating pars planitis is projected to develop at a faster rate as a result of additional factors such as the rising geriatric population and the demand for more potent treatments. The pars planitis market has also grown due to high disposable income and changing lifestyles of people in developed and developing nations. The pars planitis market benefits from the increase in research and development efforts and the introduction of successful therapies. Additionally, the market for treating pars planitis will grow at a faster pace in the future due to the high unmet need for current treatments and advancements in medical technologies.
However, high treatment costs and a lack of infrastructure in low-income nations hamper the revenue growth of the global pars planitis market. The development of the pars planitis market is also impeded by the complications associated with the condition.
Pars Planitis Market Ecosystem
The global pars planitis market is analyzed from three perspectives: therapy, distribution channel, and region.
Pars Planitis Market by Therapy
[767565]
Based on the therapy, the global pars planitis market is segmented as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). Immunomodulatory therapy, and others.
The corticosteroids segment accounted for the major revenue share of the global pars planitis market in 2022. In terms of uveitis, corticosteroids are a two-edged weapon. They are crucial in the early stages of uveitis treatment when prompt control of inflammation is necessary. Systemically or locally, steroids can be administered using topical drips, intraocular injections, or intravitreal suspensions, each of which has advantages and disadvantages. Prednisolone acetate suspension (1%), dexamethasone suspension (0.1%), difuprednate emulsion (0.05%), loteprednol etabonate suspension (0.5%), and fuorometholone (FML) suspension (0.1%) are the most popular topical corticosteroid treatment of choices. Periocular injections of corticosteroids can be made either trans-septal or into the sub-Tenon’s space. When treating macular edema, it is important to inject the medication as close to the macula as possible; otherwise, systemic side effects may occur. This method of delivery is advantageous in that it prevents systemic side effects and concentrates the steroid medication where it will be most effective.
However, all corticosteroids have the potential to have significant side effects, from cataracts and glaucoma brought on by local treatment to the potentially fatal side effects of high-dose, long-term systemic steroids, such as diabetes and adrenal insufficiency. Most of the time, using corticosteroids, either locally or systemically, is not a suitable choice for long-term uveitis treatment. In such chronic instances, steroid-free immunomodulating therapy is commonly the best choice.
Pars Planitis Market by Distribution Channel
Based on the distribution channel, the global pars planitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global pars planitis market in 2022. Hospital pharmacies contribute significantly to patient care by cooperating with doctors, nurses, and other healthcare providers to offer appropriate drugs and supplies in accordance with prescribed treatment procedures. It ensures better patient outcomes, assisting hospitals in exceeding patient satisfaction goals. According to the American Society of Health-System Pharmacists’ national survey on hospital pharmacy practice, hospital pharmacists play a key role in patient care and supply more medication-related patient transition-of-care interventions, 24/7 medication order review, and medication counseling. Furthermore, the hospital pharmacy significantly impacts the economics of health expenses. The hospital pharmacy now provides both drug monitoring and medication information. Moreover, several government initiatives, such as subsidized medicines, assist patients in purchasing expensive drugs for rare diseases, such as congenital hyperinsulinism, regardless of income. As a result of the rising drug prices and a lack of medicines in retail pharmacies, patients prefer hospital pharmacies, resulting in a significant increase in the revenue of the segment.
Pars Planitis Market by Region
Based on the region, the global pars planitis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounted for the largest revenue share of the global pars planitis market in 2022. The pars planitis market in North America is likely to be influenced by the rise in disease prevalence, an increase in the number of people of American ancestry, growth in awareness, advancements in diagnostic techniques, enhancements in healthcare services, accelerated economic development in developing nations, and increase in research and development activities. North America dominates the global pars planitis market due to a larger patient pool, an increase in the number of diagnostic procedures, the existence of top manufacturers, and rapid drug development.
Asia Pacific is expected to offer lucrative opportunities to the pars planitis market during the forecast period. The market is anticipated to be driven by an increase in demand for supportive care therapeutics due to a rise in healthcare costs in the region, the expansion of the medical tourism industry, the augmentation of the pharmaceutical industry, and a high acceptance rate for novel products in the region.
In Europe, the pars planitis market is growing significantly owing to the increasing prevalence of the disease along with the rising healthcare expenditure. Pars planitis is one of the main causes of blindness in middle age, affecting 5%–10% of individuals annually in Europe.
Pars Planitis Market Competitive Landscape
The global market for pars planitis is highly competitive with an increase in strategies, such as product launches, mergers, and acquisitions by players. One of the key development strategies many businesses emphasize is applying better therapeutics, such as immunomodulatory therapies, getting those products approved, and engaging in other activities, such as events and patents. The market defined acquisition, partnership, and collaboration as inorganic development tactics. Given the increasing global market demand for pars planitis therapeutics, these actions have increased the likelihood of having lucrative prospects in the future.
The prominent players in the global pars planitis market are:
Pars Planitis Market Strategic Developments
Pars planitis is a disease that causes inflammation of the uvea, or center layer of the eye. The uvea connects to the pupil, ciliary body, and choroid. Additionally, the uvea houses the retina’s blood vessels. The restricted region (pars plana) between the colored part of the eye (iris) and the choroid becomes inflamed in pars planitis.
The increasing prevalence and rising disease awareness are the key trends governing the revenue growth of the global pars planitis market.
Key companies operating the global pars planitis market are Quantum Cryogenics, Pacira BioSciences, Inc., ATRICURE, INC., BTG International Inc., and Zimmer MedizinSysteme GmbH.
The high cost of treatment and lack of knowledge are major factors hindering the revenue growth of the pars planitis market.
The global pars planitis market is expected to grow at a revenue CAGR of 6.5% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domai